How much is a Gilead Sciences share worth?
One share of GILD stock can currently be purchased for approximately $70.25. How much money does Gilead Sciences make? Gilead Sciences has a market capitalization of $88.12 billion and generates $24.69 billion in revenue each year.
What is Gilead Sciences'stock symbol?
What is Gilead Sciences' stock symbol? Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD." Who are Gilead Sciences' major shareholders? Gilead Sciences' stock is owned by a variety of retail and institutional investors.
When did Gilead Sciences'dividend increase in 2021?
The most recent change in Gilead Sciences's dividend was an increase of $0.03 on Thursday, February 4, 2021. What is Gilead Sciences's dividend payout ratio? View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks.
When was Gilead Sciences founded?
The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA. Is Gilead Sciences Stock a Buy Now?
See more
Is it a good time to buy Gilead stock?
Gilead stock is not a buy as of December 2020 based on the metrics that other big winning stocks showed at the beginning of major price runs. Investors should look for stocks that beat expectations while growing sales and earnings.
Is GILD a buy or sell?
Out of 12 analysts, 2 (16.67%) are recommending GILD as a Strong Buy, 2 (16.67%) are recommending GILD as a Buy, 7 (58.33%) are recommending GILD as a Hold, 0 (0%) are recommending GILD as a Sell, and 1 (8.33%) are recommending GILD as a Strong Sell. What is GILD's earnings growth forecast for 2022-2024?
Is Gilead Sciences publicly traded?
Gilead Sciences (GILD) Stock Moves -0.51%: What You Should Know. In the latest trading session, Gilead Sciences (GILD) closed at $62.34, marking a -0.51% move from the previous day.
What sector is GILD in?
Health CareKey DataLabelValueExchangeNASDAQ-GSSectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations1 Year Target$71.0014 more rows
What is the target price for Gilead stock?
Stock Price TargetsHigh$90.00Median$68.00Low$56.00Average$69.43Current Price$61.01
What is the outlook for Gilead Sciences?
The 22 analysts offering 12-month price forecasts for Gilead Sciences Inc have a median target of 68.50, with a high estimate of 90.00 and a low estimate of 56.00. The median estimate represents a +10.43% increase from the last price of 62.03.
Is Gilead a good company?
Gilead Sciences is a great company to work for. It has great company culture as well as a good work-life balance. Gilead is definitely the leader in infectious diseases. The company is actively expanding its oncology pipeline.
When did Gilead go public?
January 1992Gilead debuted on the NASDAQ in January 1992. Its initial public offering raised $86.25 million in proceeds. In June 1996, Gilead launched Vistide (cidofovir injection) for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS.
What does Gilead Science do?
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we seek to improve the care of patients living with life-threatening diseases around the world.
Should I buy or sell Gilead Sciences stock right now?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last twelve months. There are currently 1 sell rat...
What is Gilead Sciences' stock price forecast for 2022?
14 analysts have issued 1 year target prices for Gilead Sciences' stock. Their forecasts range from $56.00 to $90.00. On average, they anticipate G...
How has Gilead Sciences' stock price performed in 2022?
Gilead Sciences' stock was trading at $72.61 at the start of the year. Since then, GILD shares have decreased by 16.3% and is now trading at $60.74...
When is Gilead Sciences' next earnings date?
Gilead Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Gile...
How were Gilead Sciences' earnings last quarter?
Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings results on Thursday, April, 28th. The biopharmaceutical company reported $2.12 ea...
How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?
Gilead Sciences declared a quarterly dividend on Monday, May 2nd. Shareholders of record on Wednesday, June 15th will be given a dividend of $0.73...
Is Gilead Sciences a good dividend stock?
Gilead Sciences(NASDAQ:GILD) pays an annual dividend of $2.92 per share and currently has a dividend yield of 4.77%. GILD has a dividend yield high...
What guidance has Gilead Sciences issued on next quarter's earnings?
Gilead Sciences issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of $6...
Who are Gilead Sciences' key executives?
Gilead Sciences' management team includes the following people: Mr. Daniel P. O'Day , Chairman & CEO (Age 58, Pay $6.09M) Mr. Andrew D. Dickinso...
How much does Gilead make?
When will Gilead Sciences release its earnings?
Gilead Sciences has a market capitalization of $85.30 billion and generates $24.69 billion in revenue each year. The biopharmaceutical company earns $123 million in net income (profit) each year or $7.09 on an earnings per share basis.
What is the dividend payout ratio for Gilead Sciences?
Gilead Sciences is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021. View our earnings forecast for Gilead Sciences.
What is Gilead Sciences?
Gilead Sciences does not yet have a strong track record of dividend growth. The dividend payout ratio of Gilead Sciences is 40.06%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 41.64% next year.
What is the P/E ratio of Gilead Sciences?
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
How much of Gilead Sciences is held by institutions?
The P/E ratio of Gilead Sciences is 12.05, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.08.
Is Gilead Sciences a buy?
78.05% of the stock of Gilead Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Who owns restricted shares of a company?
Gilead Sciences has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 10 buy ratings, 5 hold ratings, and no sell ratings.
When are actual numbers added to the table?
Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
How to calculate restricted stock?
Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Source: Kantar Media
What is Gilead Sciences?
To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. A company's dividend expressed as a percentage of its current stock price.
Does market cap include convertible securities?
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C . The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination dru
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel In Late March
What is Gilead Sciences's dividend yield?
Here's a roundup of top developments in the biotech space over the last 24 hours.
What track record does Gilead Sciences have of raising its dividend?
The current dividend yield for Gilead Sciences (NASDAQ:GILD) is 3.96%. Learn more
Recently Viewed Tickers
Gilead Sciences (NASDAQ:GILD) has increased its dividend for the past 6 consecutive years.
Gilead Sciences Inc
Visit a quote page and your recently viewed tickers will be displayed here.
